3839-20-1 Usage
General Description
5-cyano-1-naphthoic acid is a chemical compound with the molecular formula C12H7NO2. It is an organic compound that belongs to the class of naphthoic acids, which are aromatic carboxylic acids. 5-cyano-1-naphthoic acid is a pale yellow solid at room temperature and is soluble in organic solvents. It is used in the synthesis of pharmaceuticals and agrochemicals. 5-cyano-1-naphthoic acid is also utilized as a fluorescent probe for detecting and quantifying Cu2+ ions in biological and environmental samples. Additionally, it has potential applications in the field of material science, particularly in the development of organic light-emitting diodes (OLEDs). Overall, this compound has various uses in different industries due to its unique properties and versatile nature.
Check Digit Verification of cas no
The CAS Registry Mumber 3839-20-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,8,3 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 3839-20:
(6*3)+(5*8)+(4*3)+(3*9)+(2*2)+(1*0)=101
101 % 10 = 1
So 3839-20-1 is a valid CAS Registry Number.
3839-20-1Relevant articles and documents
Discovery of novel, orally active dual NK1/NK2 antagonists
Bernstein, Peter R.,Aharony, David,Albert, Jeffrey S.,Andisik, Donald,Barthlow, Herbert G.,Bialecki, Russell,Davenport, Timothy,Dedinas, Robert F.,Dembofsky, Bruce T.,Koether, Gerard,Kosmider, Benedict J.,Kirkland, Karin,Ohnmacht, Cyrus J.,Potts, William,Rumsey, William L.,Shen, Lihong,Shenvi, Ashok,Sherwood, Scott,Stollman, David,Russell, Keith
, p. 2769 - 2773 (2007/10/03)
Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.
